On August 7, 2025, Telomir Pharmaceuticals announced that its drug candidate, Telomir-1, showed promising in vitro results by inhibiting key enzymes that drive tumor growth and various diseases, suggesting potential treatments for cancer, autoimmune conditions, and neurodegeneration.